NIH Pancreatic Cancer Detection Consortium (4.6.18)

July 5, 2017
By: Julie Poucher Harbin, Writer, DCI

The Pancreatic Cancer Detection Consortium (U01)

Funding Agency: National Institutes of Health 

This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions. This initiative addresses one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The PCDC is intended to support research for the development and testing of new molecular and imaging biomarkers for identifying patients at high risk for PDAC (because of genetic factors or the presence of precursor lesions) who could be candidates for early intervention. The research will be conducted by individual multi-disciplinary research teams, hereafter called Units. The Units will undertake studies on the following areas: identification and testing of biomarkers measurable in bodily fluids for early detection of PDAC or its precursor lesions; determine which pancreatic cysts are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; conduct biomarker validation studies; and collect longitudinal biospecimens for the establishment of a biorepository. All Units are expected to participate in collaborative activities with other Units and share ideas, specimens and data within the Consortium.

Application Deadlines:  

  • Letter of Intent Due Date(s): 30 days before application due date
  • Application Due Date(s): September 21, 2017, April 6, 2018, by 5:00 PM local time of applicant organization

Eligibility: Faculty

For more information: